Results 161 to 170 of about 119,004 (251)
SERS-Based Immunoassays for the Detection of Botulinum Toxins A and B Using Magnetic Beads. [PDF]
Sensors (Basel), 2019 Kim K, Choi N, Jeon JH, Rhie GE, Choo J.
europepmc +1 more source
Clinical Case Reports, Volume 14, Issue 11, November 2026.ABSTRACT We report a woman with anti‐GAD‐positive Stiff Person Syndrome undergoing two multidisciplinary neurorehabilitation admissions. A Transactional Analysis‐informed neuropsychotherapeutic intervention supported emotional adaptation and goal transition from recovery to adaptation.
Marianna Contrada +9 more
wiley +1 more source
Patient Characteristics and Real-World Use of Botulinum Toxins for the Treatment of Cervical Dystonia, Blepharospasm, and Hemifacial Spasm. [PDF]
Toxins (Basel)Hast MA +5 more
europepmc +1 more source
Report of Adverse Events Associated With Cutaneous Procedures: Update From the CAPER Registry
Lasers in Surgery and Medicine, Volume 58, Issue 9, Page 796-801, November 2026.ABSTRACT Objectives To systematically evaluate submissions to the CAPER database by analyzing procedural context, characteristics of reported adverse events (AEs), and provider involvement in order to identify patterns with potential implications for patient safety.
Sabrina S. Smith +9 more
wiley +1 more source
Neurourology and Urodynamics, Volume 45, Issue 8, Page 1476-1478, November 2026.ABSTRACT Aims To summarize current evidence on β3‐adrenoceptor agonists for managing neurogenic lower urinary tract dysfunction (NLUTD), focusing on their efficacy, safety, and clinical role in optimizing bladder storage and protecting upper tracts. Methods Evidence from randomized controlled trials, meta‐analyses, and observational studies in spinal ...
Sharon E. Fishberg, Rano Matta
wiley +1 more source
Neurourology and Urodynamics, Volume 45, Issue 8, Page 1482-1486, November 2026.ABSTRACT Introduction Refractory neurogenic lower urinary tract dysfunction presents an obstinate clinical problem. For patients who fail nonsurgical measures, we advocate for bladder‐sparing, continent urinary diversion as the optimal approach to management.
Brian W. Chao, Sean P. Elliott
wiley +1 more source
“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox
Neurourology and Urodynamics, Volume 45, Issue 8, Page 1479-1481, November 2026.ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan +2 more
wiley +1 more source
Neurourology and Urodynamics, Volume 45, Issue 8, Page 1500-1506, November 2026.ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang +2 more
wiley +1 more source
Neurourology and Urodynamics, Volume 45, Issue 8, Page 1545-1555, November 2026.ABSTRACT Objective To synthesize the evidence on the efficacy and safety of mirabegron and intradetrusor onabotulinumtoxinA (BoNT‐A) as separate interventions for overactive bladder (OAB) in Parkinson's disease (PD). Methods A systematic review and meta‐analysis with parallel synthesis of two distinct interventions was conducted of randomized and ...
Hussain Arshad +4 more
wiley +1 more source
Botulism is a disease involving intoxication with botulinum neurotoxins (BoNTs), toxic proteins produced by Clostridium botulinum and other clostridia. The 150 kDa neurotoxin is produced in conjunction with other proteins to form the botulinum progenitor
core